Authors
Shayan Forghani, Amirhossein Shahsavand, Ardin Damavandi Kamali, Arian Ghasemloo, Reza Samiee, Mohammadamin Kharaghani, Saba Akbarzadeh, Fatemeh Mahdavi Sabet, Arman Forghani, Mohammadreza Rostami, Amir Hossein Mirhosseini, Sohrab Aghabeigi, Tahereh Rostami, Ghasem Janbabai
Published in
Stem cell research & therapy. Volume 17. Issue 1. Aug 24, 2026. Epub Aug 24, 2026.
Abstract
Optimal donor selection for haploidentical HCT remains undefined, often relying on structural matching paradigms derived from unrelated donor transplantation. We aimed to evaluate the prognostic value of Human Leukocyte Antigen (HLA) features regarding outcomes of hematopoietic cell transplantation (HCT). We performed a PRISMA 2020-compliant, PROSPERO-registered systematic review (CRD420251088497) of PubMed, Embase, Web of Science, and Cochrane. We included clinical studies of haploidentical HCT for hematologic malignancies evaluating HLA-related factors and transplant outcomes. Two reviewers independently screened, extracted data, and assessed quality (Newcastle-Ottawa Scale). Hazard ratios were pooled in R using inverse-variance meta-analysis with common or random effects models based on heterogeneity (I²). In this systematic review and meta-analysis of 31 studies, we identified distinct immunogenetic determinants of relapse and survival. HLA-DRB1 mismatches in the graft-versus-host direction were associated with a reduced risk of relapse (HR, 0.74; p < .001), an effect enhanced by concurrent HLA-DQB1 matching. In contrast, HLA-B leader mismatches were linked to inferior overall survival (HR, 1.24; p = .001) and higher non-relapse mortality (HR, 1.48; p < .001). Non-permissive HLA-DPB1 mismatches in the GVH direction were associated with improved disease-free survival without increasing acute GVHD. Advanced computational approaches, including eplet mismatch load, showed inconsistent associations with outcomes compared with locus-specific functional matching. These findings support shifting from allele counting to functional selection. We propose a hierarchical strategy: first, prioritize innate safety (matching HLA-B leader) to minimize NRM, then target adaptive efficacy (mismatching HLA-DRB1) to maximize graft-versus-leukemia effects.
PMID:
43053219
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0